Mexico Medical Device Registration Roadmap: Ten Steps

1. Key takeaways

The complete Mexican market access chain can be broken into ten steps: determine the product characterization → determine the risk class → check placement under the low-risk agreement annexes → appoint the registration holder (MRH) → select the registration pathway → prepare the documentation (foreign manufacturers follow RIS Article 180) → pay the official fee → submit through DIGIPRiS → respond to deficiency requests and receive the sanitary registration → obtain the import permit and start post-market obligations. When the first three steps go wrong, everything after them is reworked. The sequence is not arbitrary: each step consumes the output of the previous one, so an error at the front does not stay local — it propagates into the dossier structure, the fee category, the holder contracts and the import logistics. Treating the ten steps as a project skeleton, with formal gates between the early definitional steps and the later executional steps, is the simplest way to keep a Mexican registration project on schedule and to make delays visible while they are still cheap to fix.

2. Legal basis

Each step rests on a specific legal source, summarized in the table below.

Keeping this table beside the project plan pays off at every gate review: each step can be closed only when its legal source and its key points are documented in the file, which makes the plan auditable end to end.

3. Expert insights

Insight 1: The holder must be settled before the documentation. The holder named on the sanitary registration is a Mexican legal entity; a foreign manufacturer cannot hold the registration itself. If the holder is not decided, the letter of authorization from the manufacturer, the business notice and the fee payer in the documentation cannot be matched to the right party, and the dossier cannot take shape. Every document in the file references the holder, so late changes to the holder cascade through powers of attorney, contracts and the submission itself. Deciding the holder arrangement first, including who signs the authorization letter and who fronts the payment, is what makes the documentation phase mechanical instead of exploratory.

Insight 2: Pathway choice affects documentation depth, not the number of obligations. The simplified pathway compresses review intensity and the depth of the summary documentation, but the obligations — sanitary registration, holder, labeling, technovigilance — are not reduced by one item. Reading the simplified pathway as a way to owe less leads directly to broken post-market chains: a company that staffs vigilance only for the standard route discovers that its simplified-pathway products carry identical duties. Budget and process design should assume the same lifecycle obligations in both routes and treat the pathway as a scheduling decision only.

Insight 3: Payment comes before submission. Official fees are charged under Article 195-A of the Federal Duties Law, and the payment receipt is part of the dossier. Fees are adjusted annually, so a project crossing a year boundary must be checked against the fee schedule of the submission year. Because the receipt is filed with the application, an incorrect amount is not a back-office problem but a dossier defect that can stall admission. Confirming the current-year fee table at the moment of payment, not at the moment of budgeting, closes that gap.

Insight 4: Holding the registration does not mean the product can be imported. Beyond the sanitary registration, each import batch also needs the import permit (filed through VUCEM). Products listed in Annex II of the 2025 agreement are exempt from the import permit, but must submit the declaration at the port of entry. Supply chains should therefore be planned product by product: registration alone does not open the border, and the import-side requirement differs across the annexes.

Insight 5: Post-market obligations start when the registration is issued. Article 262 Bis of the LGS, added by the amendment decree published in DOF 2026-01-15, states expressly that post-market surveillance activities must begin from the date COFEPRIS issues the medical device registration. There is no ramp-up period between approval and obligation, so the technovigilance arrangements must be live on the day the registration arrives, not the day of first shipment.

4. Practical recommendations

1. Manage the project on a single ten-step Gantt chart and set independent review gates on the first three steps, so characterization, classification and annex placement are confirmed before documentation work begins.
2. Separate the holder arrangement from commercial channels and appoint the registration holder independently, to avoid later transfer disputes.
3. Prepare the documentation packages for the simplified and standard pathways separately, remembering that the simplified pathway still requires a summary dossier.
4. Calculate fees against the fee schedule of the submission year and leave room in the budget for annual adjustments.
5. Schedule import permits batch by batch and keep a port declaration template ready for Annex II products.
6. Start the technovigilance unit operating records on the day the registration is issued.

5. Verification checklist

• □ Ten-step milestones entered into the project plan
• □ Review gates set on the first three steps (characterization / classification / annex check)
• □ Registration holder appointed and kept independent of commercial channels
• □ Pathway selected and documentation depth matched
• □ Official fees calculated against the submission-year fee schedule
• □ Import permit or Annex II declaration scheduled
• □ Technovigilance unit operating from the date the registration is issued

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com